AIM: To investigate whether the magnetic resonance imaging (MRI) tumour regression grading (mrTRG) scale can be taught effectively resulting in a clinically reasonable interobserver agreement (κ>0.4; moderate to near perfect agreement).
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organised for radiologists to assess regression of rectal cancers on MRI staging scans. A range of mrTRGs on 12 patient scans were used for assessment.
RESULTS: Kappa agreement ranged from 0.14-0.82 with a median value of 0.57 (95% CI: 0.37-0.77) indicating good overall agreement. Eight (26%) radiologists had very good/near perfect agreement (κ>0.8). Six (19%) radiologists had good agreement (0.8≥κ>0.6) and a further 12 (39%) had moderate agreement (0.6≥κ>0.4).
Five (16%) radiologists had a fair agreement (0.4≥κ>0.2) and two had poor agreement (0.2>κ). There was a tendency towards good agreement (skewness: 0.92). In 65.9% and 90% of cases the radiologists were able to correctly highlight good and poor responders, respectively.
CONCLUSIONS: The assessment of the response of rectal cancers to chemoradiation therapy may be performed effectively using mrTRG. Radiologists can be taught the mrTRG scale. Even with minimal training, good agreement with the central reviewer along with effective differentiation between good and intermediate/poor responders can be achieved. Focus should be on facilitating the identification of good responders. It is predicted that with more intensive interactive cased-based learning a κ>0.8 is likely to be achieved. Testing and retesting is recommended.
INTRODUCTION
The treatment for rectal cancer has improved and has led to better survival outcomes over the last three decades. The reasons for this are multifactorial and include better understanding of pelvic anatomy 1 and surgical techniques 2 , earlier diagnoses 3 , neoadjuvant or adjuvant therapies 4 , and improved imaging 5 . Response M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT of tumours to neoadjuvant therapy has also allowed more sphincter-sparing procedures 6 with the additional potential for deferral of surgery 7, 8 .
The degree of tumour response has been shown to be an important prognosticating factor 9, 10 . This response may be classified by several methods including:
downstaging, most commonly according to the TNM classification 11 ; downsizing, usually by Response Evaluation Criteria In Solid Tumours (RECIST) 12 ; and, by regression grading 13, 14 . Tumour regression appears to be an independent predictor for survival; 1, 15 however, there are several scales evident in the literature 13, 14, [16] [17] [18] [19] [20] [21] [22] [23] [24] .
This has resulted in confusion as to the precise definition of a "poor", "intermediate" or "good" responder; 25 consequently, there is a wide variation in the reported disease-free survival (DFS) and overall survival (OS) 16, 17, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
More recently magnetic resonance imaging (MRI) has been used for tumour regression grading (mrTRG) with a more representative DFS of 31-68% and OS 27-59% for poor responders and DFS of 64-83% and OS of 72-90% for good responders 42, 43 . The mrTRG scale can be accurately taught and utilised by other experienced gastrointestinal radiologists 44 , achieving a κ of 0.6 for mrTRG, which was better than the interobserver agreement reported for T-staging at MRI 44 . The purpose of this article is to investigate the interobserver agreement between a central reviewer and 35 radiologists newly taught in mrTRG assessment during a training workshop.
MATERIALS AND METHODS
Hypothesis and sample size
The hypothesis of the present study was that the mrTRG scale can effectively be taught if a clinically reasonable interobserver agreement (κ>0.4; moderate to near M A N U S C R I P T
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(poor/fair agreement).
The technique described by Gwet 45 was used to determine the sample size, which assumes a chance probability of 0%. To achieve a minimum κ of 0.4 with a relative error of 20%, a minimum sample size of 156 is required. There were 35 radiologists at two separate workshops, and so a sample of 12 patients was chose, ensuring 420 comparisons made with the central reviewer.
Patients and imaging
A senior radiologist reviewed a patient and imaging database at a cancer centre. Following this, the radiologists assessed the pre-and post-treatment scans of 12 patients and gave them an mrTRG score using a standardised proforma. The detail in the proforma used the same mrTRG scale (Fig. 1 ). The two proformas differed only in the first being more detailed, adding extra points that the radiologist could consider in their assessment of the case. The mrTRG score in both cases relied on the same tumour visible score, which is the information used to give the mrTRG score. There was a slight difference in the TRG score 2 between "minimal" and M A N U S C R I P T
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"none" on first and second proformas, but the other scores were all unchanged. The additional points of fibrosis, mucin, and lymph nodes on the first proforma were for consideration only. On the second course, these were removed to encourage people to concentrate only on the relevant question of remaining tumour visible. No other pathological or clinical information was given to those participating. Images were assessed on a high-definition reporting monitor. The participants performed the assessment independently and were blinded to the correct assessment until the end of proforma completion. After handing in the proforma, the answers were available and several cases were reviewed in a group setting. No data were collected to identify individual radiologists. Completed data forms were collated and then compared to the reference standard assessment performed by a senior radiologist.
mrTRG scale
The mrTRG scale is based on a regression scale originally described for postoperative resection specimens 13 and uses a five-point scale ( Table 1) 48 and IBM SPSS version 22.0 (2013; IBM, NY, USA) 49 . Cohen's κ level was used to calculate the interobserver agreement between the reference standard and individual radiologists and also to obtain an overall value. A value of p<0.05 was chosen as the significance level for κ statistics and tests whether the agreement is due to chance, therefore, if p<0.05 it proves the null hypothesis that the agreement would not be expected by chance alone 50 . The value of κ statistics was interpreted according to Altman 51 . Agreement lies between 0 and 1, where 0 is indicative of no agreement and 1 indicates complete agreement. "Very good/near perfect" agreement is considered as a κ of 0.81-1.00; "good" agreement as a κ of 0.61-0.80;
"moderate" agreement as a κ of 0.41-0.60; "fair" agreement as a κ of 0.21-0.40;
"poor" agreement as a κ of <0.2. Rarely, a negative κ is observed, which indicates that the interobserver agreement is less than would be expected by chance and is interpreted as no agreement 52 . A measure of skewness to assess normal distribution was calculated to investigate whether the trend was towards a higher or lower κ and considered significant if the standard error of the skewness was less than half the overall value of the skew 53 . Forest plots were used for graphical display using
Comprehensive Meta-Analysis (Biostate, Englewood, NJ, USA) 54 .
RESULTS
Thirty-five radiologists completed the proforma for mrTRG scoring (Fig. 1 ). Two radiologists misunderstood the proforma (achieving a negative κ) and were excluded from the analysis. There were seven missing data entries leaving 389 assessments on 12 patients. There were six male and six female patient images. One patient had mrTRG 1, three had mrTRG 2, three had mrTRG 3, three had mrTRG 4, and two patients had an mrTRG5. This entailed four "good" responders (mrTRG 1-2) and 
Patient demographics
Patient demographics can be seen in Table 2 . There were six men and six women.
Mean age was 75 years (54-93 years). One patient had metastases at presentation and was a poor responder (mrTRG 4). Five patients were deferred for surgery, four of which were considered good responders (mrTRG 1 and 2). One patient (originally mrTRG 3) was deferred for surgery after a repeat MRI showed ongoing response. All patients who had a good response were given consolidation chemotherapy and underwent close follow-up.
Ability to differentiate between good and intermediate/poor responders
Results of the κ statistic for each radiologist can be seen in Table 3 and The median interobserver agreement from the first workshop was 0.61 (range=0.38-0.82) and for the second it was 0.53 (range=0.14-0.80). As the comparisons were individual comparisons with the reference standard, it was not statistically feasible to directly compare the two; however, the difference does not constitute a drop in the kappa agreement categories and would be considered within an acceptable variance.
Ability to identify good and poor responders as separate groups
According to central review, there were four patients with mrTRG 1-2 (good responders); with 33 radiologists there were a total of 129 assessments (three assessments were missing). In 65.9% of cases, the radiologists were able to identify good responders correctly in agreement with the study standard. There were eight patients with mrTRG 3-5 (intermediate/poor responders); with 33 radiologists there were a total of 260 assessments (four assessments were missing). In 90% of cases, the radiologists were able to identify intermediate/poor correctly in agreement with the study standard. This suggests that radiologists are better at identifying poor responders than identifying good responders; this has a marked subsequent effect on the interobserver agreement.
DISCUSSION
Identifying an accurate and reproducible assessment of regression after CRT is an important factor in rectal cancer management. Although this has usually been conducted with pathological assessment systems, mrTRG has the advantage of M A N U S C R I P T
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potentially affecting management prior to surgery, and therefore, provides a window of opportunity to act on this information.
Main findings
The present study has shown that after a short period of training, most radiologists This indicates radiologists are more likely to misinterpret fibrosis as residual tumour and greater experience is necessary to have the confidence to report no visible tumour.
Importance of this study
Traditionally complete pathological response is considered to be reflective of better long-term outcomes 15 . There has been extensive work on attempting to classify patients into good and intermediate/poor response to try and personalise treatment options and inform follow-up protocols; however, this has remained challenging due to a range of pTRG scales that assess regression 55 using post-surgical specimens 13, 14, [16] [17] [18] [19] [20] [21] [22] [23] . Although traditionally histopathology was considered the reference standard, a reference standard is typically defined as any technique that predicts outcomes accurately. mrTRG has shown better correlation to survival outcomes in the literature, and therefore, is an important tool in directing treatment, and currently,
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would be viewed as the preferred reference standard. Given the role of mrTRG, it would be useful to establish whether it can be taught and utilised effectively by other radiologists. The present study has shown that good clinical κ agreement can be achieved with minimal training. Further focus could concentrate on facilitating the ability to identify good responders.
Appraisal of evidence
The results of the present study are comparable with other studies, including the MERCURY study, 43, 44 reporting κ agreement of 0.55-0.65. The present results were not dissimilar to these values, and this highlights that the mrTRG scale can be replicated in a range of settings and may be taught effectively by the techniques of standalone workshops; essentially validating its use by other radiologists in different settings.
Furthermore the present study has shown that mrTRG is consistent and reliable in differentiating between good and intermediate/poor responders. This is higher than reported histological grading systems, which tend toward poor agreement using different histological scales with overall κ values ranging from 0.28-0.38 and approximate median κ values for different scales of 0.24, 0.42, and 0.58 56 . One issue regarding pathology TRG scales is that there is a perception that it may not actively affect the ongoing management of patients despite its mandatory requirement in reports 57 . The use of mrTRG allows the multidisciplinary team (MDT) to potentially change management decisions preoperatively and consider the use of consolidation chemotherapy and non-operative therapy 58 .
Strengths of the study M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
The main strength of the present study is the sample size of 35 radiologists and 12 patient images giving an effective sample size of 413 (seven missing assessments).
This ensured effective statistical analyses to be performed. The teaching setting was part of a workshop attended by radiologists who had an interest in learning or improving their skills in reporting rectal cancer MRI, but none had prior experience in using this mrTRG system. The images were high quality and assessed on reporting monitors, allowing the assessments to be performed according to the mrTRG scale without any confounding image-related factors. The radiologists were also blinded to the reference standard until the end of the assessment. The advantage of establishing mrTRG as the reference standard assessment is to effectively offer management specifically tailored to patients and may include the option of nonoperable management or potentially further chemoradiotherapy, with a view to increasing sphincter-saving procedures.
Limitations and heterogeneity of this study
The short period of teaching and assessment may falsely downgrade the κ agreement. Ideally, the assessment could be extended to multiple workshops with an initial period of central review, as there is likely to be a learning curve, 43 even though the initial results are encouraging. As part of a full-day course on rectal MRI staging, the mrTRG was only presented as a brief lecture and there was no hands-on casebased teaching until after the assessments had been completed. The lecture and proforma were also altered slightly between the two workshops. The radiologists had differing degrees of experience, including some who had no prior experience reporting rectal MRI, which may reflect the range of agreement for individual radiologists.
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The costs of MRI following treatment may not always be reimbursed in different healthcare systems. Rationing of healthcare spending and limitation of MRI examinations until the test can be proven definitively as a clinical necessity is also a factor in some centres. The lack of confidence in radiological interpretation of posttreatment imaging has also been cited as a contributing factor 59, 60 .
Implications for clinical practice and future work
The present study indicated that post-treatment assessment of tumour regression (mrTRG) can be taught effectively in a short time period and as the body of evidence increases regarding patient assessment using MRI, subsequent implementation and adoption of the mrTRG scale may be relatively seamless. The use of mrTRGdirected management to offer this stratified approach to treatment will be tested in the multicentre randomised TRIGGER trial (magnetic resonance Tumour Regression Grade (mrTRG) as a novel biomarker to stratify between Good and poor responders following chemoradiotherapy in Rectal cancer). This imminent trial will investigate the initial MRI to guide neoadjuvant therapy requirement and operative planning,
including influencing factors such as mrEMVI. A second MRI after neoadjuvant therapy will examine mrTRG. A good responder may be offered deferral of surgery and the poor responders will be offered further treatment or surgery.
In conclusion, the assessment of the response of rectal cancers to chemoradiation therapy may be performed effectively using mrTRG. Radiologists can be taught the • Inter-observer agreement of radiologists was assessed, when using the MRI tumour regression scale to determine response of rectal cancers to chemoradiotherapy
• Kappa agreement had a median value of 0.57 (95% CI: 0.37-0.77) indicating an overall good agreement.
• In 65.9% and 90% of cases the radiologists were able to correctly highlight good and poor responders respectively.
• Radiologists can be taught the mrTRG scale and even with minimal training good agreement and effective differentiation between good and intermediate/poor responders can be achieved.
• Focus should be on facilitating the identification of good responders.
